Corp Recap Dear Shareholder
The year 2020 draws to a close an unprecedented year of growth for StageZero. You may recall early in the year the Company was able to pivot to offering COVID-19 tests in addition to its early stage cancer tests. This has presented many new opportunities for revenue generation and partnerships. The third quarter was particularly robust for the Company.
2020 Highlights include:
- Q3 received revenue of US$1.5M, with additional testing revenue billed for the quarter.
- Clarus Securities initiated coverage on the Company.
- Partnerships around testing increased from 5 in Q2 to over 50 in Q3 for COVID19.
- Expanded lab capabilities and staff. This is ongoing into Q4/Q1.
- Testing offering expanded to include remote supervised saliva tests and a respiratory panel.
- Travel partnerships expanded with StageZero becoming a preferred testing partner for Barbados; as well as a testing partner for China and the State of Hawaii.
- Validation of Aristotle as a Lab Developed Test (“LDT”) is underway.
- Closed two prospectus offerings for gross proceeds of $11.8M.
I invite you to continue to follow the Company on its social media accounts and in the broader media. With the launch of Aristotle in Q1 2021, the Company anticipates 2021 to be pivotal.
Rebecca Greco
Investor Relations